112522-64-2 | 4-Acetylamino-n-(2'-aminophenyl)benzamide

Packsize	Purity	Availability	Price	Discounted Price
5mg	98%	in stock	$30.00	$21.00
10mg	98%	in stock	$56.00	$39.00
100mg	98%	in stock	$121.00	$85.00
250mg	98%	in stock	$175.00	$123.00
1g	98%	in stock	$418.00	$293.00

Description

• Catalog Number: AD40360
• Chemical Name: 4-Acetylamino-n-(2'-aminophenyl)benzamide
• CAS Number: 112522-64-2
• Molecular Formula: C15H15N3O2
• Molecular Weight: 269.2985
• MDL Number: MFCD00866266
• SMILES: CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N

Computed Properties

• Complexity: 351
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 20
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 3
• XLogP3: 1.3

Upstream Synthesis Route

4-(Acetylamino)-N-(2-aminophenyl)benzamide, commonly known as $name$, is a versatile compound widely utilized in chemical synthesis for its key role in the creation of various pharmaceuticals, organic compounds, and advanced materials. This compound is prized for its ability to serve as a crucial building block in many synthetic pathways due to its unique structure and reactivity. Through its participation in coupling reactions, amide bond formations, and various functional group manipulations, $name$ facilitates the production of intricate molecular structures essential in drug discovery, material science, and other fields requiring precise chemical design. Its strategic placement and functional groups make $name$ a valuable asset in the hands of chemists seeking to synthesize complex molecules efficiently and with high precision.

Literature

• Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis.

  Chemistry & biology 20120622

• Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL.

  Carcinogenesis 20111001

• Interpreting clinical assays for histone deacetylase inhibitors.

  Cancer management and research 20110101

• Inside HDAC with HDAC inhibitors.

  European journal of medicinal chemistry 20100601

• Chemical phylogenetics of histone deacetylases.

  Nature chemical biology 20100301

• A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells.

  Biochemical and biophysical research communications 20100205

• New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.

  Journal of hematology & oncology 20090101

• The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.

  Critical reviews in oncology/hematology 20081001

• Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro.

  Journal of medicinal chemistry 20080710

• CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo.

  Oncology reports 20080601

• Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.

  Current medicinal chemistry 20080601

• Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.

  Bioorganic & medicinal chemistry 20080315

• Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).

  Bioorganic & medicinal chemistry letters 20080201

• Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.

  Journal of medicinal chemistry 20071115

• Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060701

• In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.

  Oncology research 20050101

• A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.

  Annals of oncology : official journal of the European Society for Medical Oncology 20041101

• Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma.

  Molecular cancer therapeutics 20030401

• Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer.

  Cancer journal (Sudbury, Mass.) 20030101

• Latent hematopoietic stem cell toxicity associated with protracted drug administration.

  Experimental hematology 20010301

• Preclinical antitumor activity of CI-994.

  Investigational new drugs 19960101